Next big news will be when they secure funding which can happen anytime - then we are talking a big jump. A very big jup. Read on.... IMO
For the second time this month, Tampa biotech Oxis Biotech Inc. has named an advisory board member with ties to activist investor Carl Icahn.
Randolph C. Read, who is president and CEO of Nevada Strategic Credit Investments LLC, joined the Oxis business advisory board, a press release said. Business advisory board members will become members of the Oxis board of directors when parent company Oxis International Inc. (OTC: OXIS) is listed on the Nasdaq exchange, the release said.
Oxis Biotech Inc. Announces Appointment of Randolph C Read to Business Advisory Board
PR Newswire
TAMPA, Fla., Sept. 24, 2015
TAMPA, Fla., Sept. 24, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today, Randolph C Read has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Randolph C. Read has been President and Chief Executive Officer of Nevada Strategic Credit Investments, LLC since 2009. Mr. Read has previously served as President of a variety of other companies, including International Capital Markets Group, Inc. Mr. Read serves on the Boards of Directors of New York REIT, Inc. (as Chairman) a NYSE listed company (NYRT), Healthcare Trust, Inc. (as Chairman), Business Development Corporation of America, and the advisory board of the Flying Food Group, LLC and has previously served on a number of public and private company boards. He has an M.B.A. in Finance from the Wharton Graduate School of the University of Pennsylvania.
"Randy is a vital part of the Oxis plan to be a major biotech company. We are excited to have him on our Advisory Board. Oxis Biotech, Inc. will continue to bring in major biotech assets and surround ourselves with key executives.
"I am very pleased to be joining the Advisory Board of Oxis Biotech, which is attempting to achieve breakthrough developments in treating various forms of cancer that could be of great value to our society," said Mr. Read.
About Oxis Biotech - Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com.
If I am not wrong, I also read somewhere that George Soros is all over OXIS, so there are already two big sharks interested on the control of OXIS, this one will make us BIG money.
News 
Market Data 
Discover 
